| Richard S. Nelson |
Mr. Richard S. Nelson is a Director & Executive VP-Corporate Development at vTv Therapeutics, Inc., an EVP-Corporate & Business Development at Vericast Corp., an Executive Vice President at MacAndrews & Forbes Holdings, Inc., a Senior Vice President-Corporate Development at MacAndrews & Forbes LLC, a Founder & Managing Director at Nelstone Ventures Advisors LLC and a President, Chief Executive Officer & Director at vTv Therapeutics LLC. He is on the Board of Directors at vTv Therapeutics, Inc., One Planet VC LLC, Think Pink Rocks, Woolsey Pharmaceuticals, Inc. and vTv Therapeutics LLC.
Mr. Nelson was previously employed as a Senior Vice President-Corporate Development by The Nielsen Co., a Managing Director-Mergers & Acquisitions by IAC/InterActiveCorp. /Old/, a President & Director by Nielsen BuzzMetrics, Inc., a Director & General Counsel by RSL COM USA, Inc., an Attorney by Skadden, Arps, Slate, Meagher & Flom LLP, a President by BuzzMetrics, Inc., an Executive Vice President-Corporate Development by NetRatings LLC, and a Chief Executive Officer by RSL Com Primecall, Inc. He also served on the board at Reply SpA.
He received his undergraduate degree from Stephen M. Ross School of Business and a graduate degree from New York University School of Law. |
| Steven Tuch |
Steven Tuch is currently the Chief Financial Officer at vTv Therapeutics, Inc. Prior to this, he was the Head of Corporate Development at Rallybio Corp. Mr. Tuch received his undergraduate degree from the University of Michigan and his MBA from Stanford Graduate School of Business. |
| Thomas Strack |
Thomas Strack is currently the Chief Medical Officer at vTv Therapeutics, Inc. He previously worked as the Vice President of Clinical Affairs at Progenics Pharmaceuticals, Inc., Head of Metabolic Clinical Development at Takeda Global Research & Development Center, Inc., Head of Research & Development at Asubio Pharmaceutical, Inc., and Chief Medical Officer at Faeth Therapeutics, Inc. He holds a doctorate degree from The Johannes Gutenberg University of Mainz. |
| Barry Brown |
Barry Brown is currently working as the Chief Accounting Officer at vTv Therapeutics, Inc. He has an undergraduate degree and an MBA from The University of North Carolina at Greensboro. |
| Vanessa McDade |
Vanessa McDade currently works as the Chief Administration Officer at vTv Therapeutics, Inc. |
| Carmen Valcarce |
Carmen Valcarce is currently the Chief Scientific Officer & Executive VP at vTv Therapeutics, Inc. and vTv Therapeutics LLC. Previously, she held positions as a Project Leader at Novo Nordisk A, Senior Vice President-Scientific Liaison at VTVX Holdings I LLC, and Principal at Excorim. She also served as an Assistant Professor at the University of Lund from 1989 to 1998. Dr. Valcarce obtained her doctorate degree from the Universidad Autónoma de Madrid in 1988. |
| Jonathan L. Isaacsohn |
Jonathan L. Isaacsohn founded CinRx Pharma LLC. He occupies the position of Chairman for vTv Therapeutics, Inc. and President, Chief Executive Officer & Director at CinRx Pharma LLC.
In the past he occupied the position of Chief Medical Officer for Teva Pharmaceutical Industries Ltd. and Executive VP-Regulatory & Medical Affairs at Medpace, Inc. |
| Paul Jai Sekhri |
Paul Jai Sekhri founded ARIAD Pharmaceuticals, Inc. in 2003, where he worked as President & Chief Business Officer from 2003 to 2004 and Cerimon Pharmaceuticals, Inc. in 2004, where he worked as President & Chief Executive Officer from 2004 to 2009. Mr. Sekhri also currently works at vTv Therapeutics, Inc., as President, Chief Executive Officer & Director from 2022, Compugen Ltd., as Chairman from 2017, Pharming NV, as Chairman, and various other companies. Mr. Sekhri also formerly worked at Lycera Corp., as President, Chief Executive Officer & Director from 2015 to 2019, Pharming Group NV, as Chairman from 2016 to 2023, Petra Pharma Corp., as Chairman, and various other companies. Mr. Sekhri received his undergraduate degree from the University of Maryland and undergraduate degree and graduate degree from the University of Maryland School of Medicine. |
| John A. Fry |
John A. Fry is President at Drexel University and President for Drexel University College of Medicine and on the board of 14 other companies.
Mr. Fry previously was President for Franklin & Marshall College, Executive Vice President of the University of Pennsylvania and Chief Operating Officer of Trustees of the University of Pennsylvania.
He received an undergraduate degree from Lafayette College, an MBA from The Leonard N Stern School of Business and an MBA from New York University. |
| Fahed Al Marzooqi |
Fahed Al Marzooqi currently works at vTv Therapeutics, Inc., as Independent Director from 2022 and G42 Healthcare, as Chief Operating Officer. Dr. Al Marzooqi also formerly worked at Cleveland Clinic Abu Dhabi, as Chief Administrative Officer. Dr. Al Marzooqi received his graduate degree from Dalhousie University. |
| Anne M. Phillips |
Anne M. Phillips is an Independent Director at Trevena, Inc., Carmot Therapeutics, Inc., Vaccitech (UK) Ltd., Barinthus Biotherapeutics Plc, and vTv Therapeutics, Inc. She is also a Director at AMAG Pharmaceuticals, Inc. and a Fellow at the Royal College of Physicians & Surgeons of Canada. Previously, she served as a Director at the Biotechnology Innovation Organization and AMAG Pharmaceuticals, Inc. She was the Head of the Infectious Diseases Program at St. Michael's Hospital and the Senior VP of Clinical, Medical & Regulatory Affairs at Novo Nordisk, Inc. She also held positions as the Chief of Infectious Diseases and Associate Professor at Wellesley Hospital and as the Vice President of Medicine Development at GlaxoSmithKline LLC. Dr. Phillips holds a doctorate degree from the University of Toronto and an undergraduate degree from the University of Western Ontario. |
| Hersh Kozlov |
Hersh Kozlov is on the board of The Bancorp, Inc. (Delaware), The Bancorp Bank, vTv Therapeutics, Inc. and vTv Therapeutics LLC and Managing Partner-Cherry Hill at Duane Morris LLP.
He previously was Managing Partner & Member-Executive Committee at Wolf, Block, Schorr & Solis-Cohen LLP.
Mr. Kozlov received an undergraduate degree from Temple University (Pennsylvania) and a graduate degree from Case Western Reserve University. |
| Howard L. Weiner |
Founder of The Brigham Multiple Sclerosis Center, Howard L. Weiner is on the board of vTv Therapeutics, Inc., vTv Therapeutics LLC and The Brigham Multiple Sclerosis Center and Professor-Neurology at Harvard Medical School.
In his past career Dr. Weiner was Co-Director-Neurologic Diseases at The Brigham & Women's Hospital, Inc.
Dr. Weiner received a doctorate from The University of Colorado School of Medicine and an undergraduate degree from Dartmouth College. |
| Keith Reginald Harris |
Keith Reginald Harris is a British businessperson who has been at the head of 13 different companies and is Executive Chairman for Global Connectivity Plc, Chairman for MeiraGTx Holdings Plc, Chairman for Keith Harris & Associates and Non-Executive Chairman & Chief Executive Officer at Semper Fortis Esports Plc. He is also on the board of vTv Therapeutics, Inc., Yesod Bio-Sciences Ltd., As Sports Management Ltd. and Sustainable Housing Solutions Pte Ltd. and Strategic Advisor at LAMF Global Ventures Corp. I.
In his past career Keith Reginald Harris occupied the position of Chief Executive Officer for GEROVA Financial Group Ltd., Managing Director at Apax Partners LLP, Managing Director & Head-Corporate Finance at Drexel Burnham Lambert, Inc., President for Morgan Grenfell, Inc., Chairman of Seymour Pierce Ltd., Chairman at Ellis Stockbrokers Ltd., Chairman at The Football League Ltd., Chief Executive Officer at HSBC Investment Bank Plc and Chief Executive Officer of Seymour Pierce Holdings Ltd.
He received an undergraduate degree from the University of Bradford and a doctorate from the University of Surrey. |
